
Microbix Biosystems Inc
TSX:MBX

Gross Margin
Microbix Biosystems Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
CA |
![]() |
Microbix Biosystems Inc
TSX:MBX
|
42.3m CAD |
58%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
327.3B USD |
71%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
155.6B USD |
64%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
135.1B USD |
78%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.3B USD |
86%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
116.3B AUD |
52%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.2B USD |
87%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD |
86%
|
Microbix Biosystems Inc
Glance View
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.

See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Microbix Biosystems Inc's most recent financial statements, the company has Gross Margin of 57.7%.